Survodutide

Status

In trials. Investigational. In Phase 3; not FDA-approved, and no approval elsewhere is listed in this entry's sources.

What it is

A GLP-1/glucagon dual agonist from Boehringer Ingelheim — the glucagon receptor engagement is aimed at liver fat and energy expenditure rather than appetite alone. It is also being studied in MASH (metabolic liver disease).

What published research measured

SYNCHRONIZE-1 (adults with obesity or overweight without diabetes) reported up to 16.6% mean weight loss at 76 weeks versus 3.2% with placebo (sponsor topline, April 2026; NEJM 2026). On 9 November 2026 the sponsor reported that SYNCHRONIZE-CVOT, in 5,530 adults with elevated cardiovascular risk, met its primary cardiovascular safety (noninferiority) endpoint and said full results were published at the same time in The Lancet (not independently reviewed here); noninferiority does not show prevention of cardiovascular events. Results from different trials cannot be compared directly.

Source

NEJM 2026;395:776–787 (SYNCHRONIZE-1); Zealand Pharma release, 9 November 2026 (SYNCHRONIZE-CVOT)

Sources

• SYNCHRONIZE-1, NEJM 2026
• SYNCHRONIZE-1 registry record NCT06066515
• Zealand Pharma release on SYNCHRONIZE-CVOT
• SYNCHRONIZE-CVOT, The Lancet (DOI 10.1016/S0140-6736(26)02140-9; not independently reviewed here)
• Primary source
• Primary source
• CDC handling principles